J&J’s Stelara Revenue Plummets as Biosimilar Competition Intensifies in 2025

Stelara; Johnson & Johnson; ustekinumab; biosimilars; revenue decline; Q2 2025; pharmacy benefit managers; formulary exclusion; drug pricing; autoimmune disease

RFK Jr. Fires Top Deputies, Reshuffles Leadership at HHS

Robert F. Kennedy Jr.; Health and Human Services; leadership reshuffle; chief of staff; personnel changes; Matt Buckham; Trump loyalists; Heather Flick Melanson; Hannah Anderson